Author:
Henshall Christopher H.,Dankó Dávid,Barham Leela,Espín Jaime,Felix Jorge,Harney Mary,Indra Peter,Mestre-Ferrandiz Jorge,de Pouvourville Gérard,Spandonaro Federico,Vončina Luka,Wilking Nils
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics and Econometrics,General Medicine
Reference18 articles.
1. World Health Organisation (WHO). Global health estimates 2019: disease burden by cause, age, sex, by country and by region, 2000–2019. Geneva: World Health Organization; 2020. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates.
2. Jemal A, Torre L, Soerjomataram I, Bray F (Eds). The Cancer Atlas, 3rd edn. American Cancer Society; 2019. https://canceratlas.cancer.org/wp-content/uploads/2019/10/ACS_CA3_Book.pdf. Accessed 16 Feb 2022.
3. Humphrey RW, Brockway-Lunardi LM, Bonk DT, et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011;103(16):1222–6. https://doi.org/10.1093/jnci/djr246.
4. Latimer NR, Towse A, Henshall C. Not cost-effective at zero price: valuing and paying for combination therapies in cancer. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):331–3. https://doi.org/10.1080/14737167.2021.1879644.
5. Persson U, Norlin JM. Multi-indication and combination pricing and reimbursement of pharmaceuticals: opportunities for improved health care through faster uptake of new innovations. Appl Health Econ Health Policy. 2018;16(2):157–65. https://doi.org/10.1007/s40258-018-0377-7.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献